Citi analyst Samantha Semenkow raised the firm’s price target on Structure Therapeutics (GPCR) to $100 from $60 and keeps a Buy rating on the shares. The positive Phase 2b data for aleniglipron gives Structure an attractive oral obesity asset, the analyst tells investors in a research note. The firm sees the drug getting “significant interest from strategics” looking to enter the oral obesity market. Citi believes aleniglipron showed “potential best-in-class” weight loss with competitive tolerability.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GPCR:
- Structure Therapeutics price target raised to $99 from $61 at Clear Street
- Structure Therapeutics announces proposed offering of $500M in ADS
- Structure Therapeutics price target raised to $90 from $50 at Stifel
- Promising Potential of Structure Therapeutics’ Aleniglipron: A Buy Rating Based on Transformative Efficacy and Strategic Innovation
- Structure Therapeutics ACCESS data validates ‘bull case,’ says H.C. Wainwright